Fwd: Personalized Cancer Therapies Come of Age; Proxy Fight Looms in Allergan-Valeant Dispute

Sent from my iPad

Begin forwarded message:

From: Kent Castle <kent.d.castle@hotmail.com>
Date: June 3, 2014 5:29:32 PM CDT
To: Choban Peter <peter.s.choban@aero.org>, Patterson James <w8ljz@aol.com>, Reason Marilou <loganlou55@yahoo.com>, Chamberlain Sharon <sharon.m.chamberlain@saic.com>, Astrology Valkyrie <astrogoddess@valkyrieastrology.com>, Martin Bobby <bobbygmartin1938@gmail.com>, Lozano Marianne <kemahsabe@comcast.net>, Tetzloff Connie <owari567@comcast.net>, Madsen Ron <ronstar@pdq.net>, Baird Darren <darren.t.baird@nasa.gov>, Rice Donna <dmcguirerice@comcast.net>, Leach Larry <ljleach@tds.net>, Bentz Jerry <bentz@sbcglobal.net>, Naftzger George <inntiqui@ffni.com>, Hultberg Jane <jhultberg@coa.edu>
Subject: FW: Personalized Cancer Therapies Come of Age; Proxy Fight Looms in Allergan-Valeant Dispute

 

---

From: reply@mail.dddmag.com
To: KENT.D.CASTLE@HOTMAIL.COM
Subject: Personalized Cancer Therapies Come of Age; Proxy Fight Looms in Allergan-Valeant Dispute
Date: Tue, 3 Jun 2014 09:01:34 -0600

AstraZeneca Antibiotic on Fast Track; Novartis Multiple Myeloma Drug Ups PFS

View this email in your browser. JUNE 03   IN THIS ISSUE   NEWS     Proxy Fight Looms in Allergan-Valeant Dispute     NEWS     AstraZeneca Antibiotic Given Fast Track, QIDP Designations     NEWS     Novartis Multiple Myeloma Drug Ups PFS in Phase 3     NEWS     Cytokinetics Posts Positive Follow-Up Results for ALS Treatment     NEWS     Cheap Drug Greatly Boosts Prostate Cancer Survival   Protect your samples The CaptairFlow HEPA filtered enclosure protects your application from contamination. Available in 4 sizes and equipped with a flexible filtering system above the enclosure to better suit your application requirements - adding a carbon filter to the filtration stack guarantees ultra clean air will flow into the hood. LEARN MORE     FEATURED STORY Personalized Cancer Therapies Come of Age     For many decades, scientific advances in cancer treatment were characterized by a slow, non-linear progress that resulted in treatments with a less than stellar ability to target cancer cells. Now, the advent of biomarker-driven drug development and the drive toward personalized medicine have provided a new approach to the treatment of advanced cancer. Read more... Share FULL STORY     NEWS Proxy Fight Looms in Allergan-Valeant Dispute Activist investor Bill Ackman said Monday that he will move to replace most of Allergan's board of directors as part of a continuing battle for control of the company. Read more...                     FULL STORY     NEWS AstraZeneca Antibiotic Given Fast Track, QIDP Designations AstraZeneca announced that the FDA has designated its novel investigational drug AZD0914 as a Qualified Infectious Disease Product and awarded its development program Fast Track status for the treatment of uncomplicated gonorrhea. Read more...   FULL STORY     NEWS Novartis Multiple Myeloma Drug Ups PFS in Phase 3 Novartis presented results from a pivotal Phase 3 trial showing a 37% improvement in PFS when using the investigational compound LBH589 (panobinostat) in combination with bortezomib and dexamethasone, compared to treatment with the same regimen with placebo, in patients with relapsed or relapsed and refractory multiple myeloma. Read more... FULL STORY     NEWS Cytokinetics Posts Positive Follow-Up Results for ALS Treatment Cytokinetics Inc. announced that additional results from BENEFIT-ALS were presented during the Joint Congress of European Neurology at the International Congress Center in Istanbul, Turkey. Read more...               FULL STORY     NEWS Cheap Drug Greatly Boosts Prostate Cancer Survival A cheap, decades-old chemotherapy drug extended life by more than a year when added to standard hormone therapy for men whose prostate cancer has widely spread, doctors report. Read more...                  FULL STORY   SUBSCRIBE • UNSUBSCRIBE • ABOUT US • ADVERTISE This email was sent by: Drug Discovery & Development 100 Enterprise Drive - Suite 600 - Rockaway, NJ 07866-2129 We respect your right to privacy - click here to view our policy. ©2014 Drug Discovery & Development. All rights reserved.